DARZALEX 1800mg Solution for injection

What is DARZALEX 1800mg

DARZALEX 1800mg is a solution for injection containing Daratumumab, a monoclonal antibody used in the treatment of multiple myeloma. It is designed to target and destroy cancer cells that express the CD38 protein, which is commonly found on the surface of myeloma cells.

This formulation of Daratumumab is administered subcutaneously, offering a more convenient and faster option for patients compared to the traditional intravenous infusions. It is often used in combination with other cancer therapies to improve treatment outcomes.

How to use DARZALEX 1800mg

DARZALEX 1800mg is administered subcutaneously, usually in the abdominal region. The usage instructions are as follows:

• Administration Route: Subcutaneous injection by a healthcare professional.
• Injection Schedule: Typically given once weekly during the initial phase of treatment, followed by less frequent injections (e.g., biweekly or monthly) as maintenance therapy.
• Premedication: Patients are often premedicated with corticosteroids, antihistamines, and antipyretics to minimize the risk of injection-related reactions.

Monitoring during and after injection is necessary to ensure patient safety and manage any potential side effects.

Mode of Action DARZALEX 1800mg

DARZALEX 1800mg exerts its therapeutic effects by binding to the CD38 protein on the surface of myeloma cells. This triggers the immune system to attack and kill the cancer cells through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

The subcutaneous formulation offers a more convenient and less invasive mode of administration while retaining the same efficacy as intravenous Daratumumab.

• Mechanism of Action: Daratumumab binds to CD38, leading to immune-mediated destruction of myeloma cells.
• Indications: Used in combination with other therapies for multiple myeloma, particularly in patients who are refractory or relapsed after prior treatments.

This subcutaneous option improves patient comfort and convenience without compromising therapeutic benefits.

DARZALEX 1800mg Interactions DARZALEX 1800mg

Before using DARZALEX 1800mg, it is important to consider potential drug interactions:

• Immunosuppressants: Combining Daratumumab with other immunosuppressive agents may increase the risk of infections.
• Live Vaccines: Avoid live vaccines during treatment as Daratumumab may reduce the immune response.
• Blood Transfusion Compatibility: Daratumumab can interfere with cross-matching blood tests, so inform healthcare providers of ongoing treatment if blood transfusions are required.

Discuss any current medications with your healthcare provider before starting DARZALEX to ensure safe use.

Dosage of DARZALEX 1800mg

The dosing for DARZALEX 1800mg is based on the treatment regimen:

• Initial Dosing: One subcutaneous injection is typically administered weekly for the first 4 to 8 weeks, depending on the patient's condition and response.
• Maintenance Dosing: The frequency of injections is gradually reduced, often to once every two to four weeks.
• Consultation: Always follow the prescribed dosing schedule provided by your healthcare provider for optimal results.

Strict adherence to the prescribed dosing regimen is crucial for effective management of multiple myeloma.

Possible side effects of DARZALEX 1800mg

Common side effects of DARZALEX 1800mg may include:

• Injection-related reactions (e.g., redness, swelling, or pain at the injection site)
• Fatigue
• Upper respiratory infections
• Fever
• Decreased blood cell counts (e.g., neutropenia, thrombocytopenia)

If severe side effects occur, such as difficulty breathing or severe allergic reactions, seek immediate medical assistance.

DARZALEX 1800mg Contraindications DARZALEX 1800mg

Before starting treatment with DARZALEX 1800mg, consider the following contraindications:

• Known hypersensitivity to Daratumumab or any of the formulation’s ingredients.
• Pregnancy and breastfeeding: Daratumumab may pose risks to the fetus or newborn, so avoid use during pregnancy unless absolutely necessary.
• Patients with active infections should have these treated before beginning Daratumumab therapy.

A comprehensive review of your medical history with your healthcare provider will ensure the safe use of DARZALEX 1800mg.

Storage of DARZALEX 1800mg

Proper storage of DARZALEX 1800mg is important to maintain its potency:

• Store in a refrigerator at 2°C to 8°C (36°F to 46°F).
• Do not freeze or shake the vial.
• Use the solution within the specified time once prepared by a healthcare provider.

Adhering to storage guidelines ensures the safe and effective administration of DARZALEX 1800mg.